Abstracts tagged "cytokines and myositis"

Abstract Number: 1032 • 2018 ACR/ARHP Annual Meeting
Aberrant Sarcoplasmic Expression of the Alarmin ‘High Mobility Group Box Protein 1” (HMGB1) in Patients with Idiopathic Inflammatory Myopathy
Jessica Day¹, Sophia Otto², Kathy Cash³, Preethi Eldi⁴, Pravin Hissaria⁵, Susanna Proudman⁶, John Hayball⁴ and Vidya Limaye⁷, ¹Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ²Pathology, Royal Adelaide Hospital, Adelaide, Australia, ³Muscle and Nerve Laboratory, SA Pathology, Adelaide, Australia, ⁴Experimental Therapeutics Laboratory, University of South Australia, Adelaide, Australia, ⁵Immunology, Royal Adelaide Hospital, Adelaide, Australia, ⁶Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁷Rheumatology, The Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Components of the innate immune system, such a High Mobility Group Box Protein 1 (HMGB1), may contribute to the initiation, perpetuation and resolution of…
Abstract Number: 287 • 2015 ACR/ARHP Annual Meeting
Interleukin-35 in Idiopathic Inflammatory Myopathies
Herman F. Mann¹, Hana Hulejova^2,3, Josef Zámecník⁴, Jaromir Hacek⁵, Mária Filková⁶, Olga Kryštufková⁷, J Vencovsky⁸ and Ladislav Senolt⁹, ¹Department of Experimental Rheumatology, Institute of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague 2, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, ³1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁴Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, ⁵Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁷Institute of Rheumatology, Department of Rheumatology of the First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁸Institute of Rheumatology, Charles University, Prague, Czech Republic, ⁹Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: Interleukin-35 (IL-35) is a newly described heterodimeric cytokine that belongs to the IL-12 family and consists of p35 (IL-12a) and EBI3 (IL-27b) subunits. IL-35…
Abstract Number: 2070 • 2013 ACR/ARHP Annual Meeting
Cytokine Profiles In Polymyositis and Dermatomyositis Complicated With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Associated Interstitial Lung Disease Or Anti-Aminoacyl tRNA Synthetase Antibody-Associated Interstitial Lung Disease
Takahisa Gono, Yasushi Kawaguchi, Hirotaka Kaneko, Yasuhiro Katsumata, Masanori Hanaoka, Sayuri Kataoka, Hidenaga Kawasumi, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Polymyositis (PM) / dermatomyositis (DM) are often complicated with interstitial lung disease (ILD). In PM/DM, complication with ILD is associated with anti-aminoacyl-tRNA synthetase (ARS),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].